KR900018064A - 피라닐 시아노구아니딘 유도체 - Google Patents

피라닐 시아노구아니딘 유도체 Download PDF

Info

Publication number
KR900018064A
KR900018064A KR1019900007840A KR900007840A KR900018064A KR 900018064 A KR900018064 A KR 900018064A KR 1019900007840 A KR1019900007840 A KR 1019900007840A KR 900007840 A KR900007840 A KR 900007840A KR 900018064 A KR900018064 A KR 900018064A
Authority
KR
South Korea
Prior art keywords
compound
cyano
alkyl
trans
benzopyran
Prior art date
Application number
KR1019900007840A
Other languages
English (en)
Other versions
KR950006155B1 (ko
Inventor
애트월 카르네일
제임스 그로버 게리
김 경순
Original Assignee
니콜라스 피. 말라테스티닉
이이. 아르. 스퀴브 앤드 산즈 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 니콜라스 피. 말라테스티닉, 이이. 아르. 스퀴브 앤드 산즈 인크. filed Critical 니콜라스 피. 말라테스티닉
Publication of KR900018064A publication Critical patent/KR900018064A/ko
Application granted granted Critical
Publication of KR950006155B1 publication Critical patent/KR950006155B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/68—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with nitrogen atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
    • C07F9/65522—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/657163—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom
    • C07F9/657181—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom the ring phosphorus atom and, at least, one ring oxygen atom being part of a (thio)phosphonic acid derivative

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

내용 없음

Description

피라닐 시아노구아니딘 유도체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (36)

  1. 하기 일바식을 갖는 피라닐 시아노구아니딘 유도체 화합물.
    식 중, a,b 및 c는 모두 탄소원자이거나, 또는 a,b 및 c중의 하나는 질소 원자 또는 -NO- 이고, 나머지는 탄소 원자들이고,
    R2는 수소, 히드록시 또는이고, R3및 R4는 각각 독립적으로 수소, 알킬 또는 아릴알킬이거나, 또는 R3및 R4는 이들에 결합된 탄소 원자와 함께 5 내지 7원 카르보시클릭 고리를 형성하고, R5는 H, 알킬, 할로알킬, 알케닐, 알키닐, 시클로알킬, 아릴알킬, 시클로알킬알킬, -CN, NO2,-COR, -COOR, -CONHR,-CONR3,-CF3, S-알킬, -SO알킬,-SO2알킬,(O-알킬)2 , 할로겐, 아미노, 치환아미노, O-알킬, OCF3, OCH2CF3, OCO알킬, -OCONR 알킬, -NRCO알킬 및 NRCOO알킬, NRCONR2(상기 기들 중에서, R은 수소, 알킬, 아릴, 아릴알킬, 시클로알킬, 또는 (시클로알킬)알킬기임)중에서 선택되고, R6는 H, 알킬, OH, O-알킬, 아미노, 치환 아미노, CN, 및 NO2중에서 선택되고, R7과 R8은 각각 독립적으로 수소, 알킬, 알케닐, 아릴, 헤테로시클로, (헤테로시클로)알킬, 아릴알킬, 시클로알킬 및 (시클로알킬)알킬, 치환 알킬기(여기서, 치환체는 알콕시, 알킬티오, 및 치환 아미노를 포함함)중에서 선택되거나, 또는 R7및 R8은 이들에 결합된 질소원자와 함게 1-피롤리디닐, 1-피페리디닐, 1-아제피닐, 4-모르폴리닐, 4-티아모르필리닐, 1-피페라지닐, 4-알킬-1-피페라지닐 또는 4-아릴알킬-1-페페라지닐기를 형성할 수 있고, 여기서, 이와 같이 형성된 기들은 각각 알킬, 알콕시, 알킬티오, 할로겐 또는 트리플루오로메틸기로 치환될 수 있으며, R9와 R10은 수소, 알킬, 알케닐, 아릴, 알릴알킬, 시클로알킬 또는 시클로 알킬알킬 중에서 선택되고, n은 1,2 또는 3이다.
  2. 1항에 있어서 다음과 같이 정의되는 화합물, 즉 a는 질소 원자 또는 -CR5이고, b 및 c는 각각 -CH-이고,
    R2는 히드록시 또는 -OCO알킬이고, R3및 R4각각은 알킬이고, R5는 전자를 끄는 기이고, R6는 수소, 알킬, O-알킬, 아미노이고, R7은 수소, 알킬, 아릴 또는 아릴알킬이고, R8은 수소이고, R9는 수소 또는 알킬이고, R10은 수소이고, n은 1 또는 2이다.
  3. 1항에 있어서 다음과 같이 정의되는 화합물, 즉, a는 질소 원자 또는 -CR5이고, b 및 c는 각각 -CH- 이고, R2는 트란스히드록시이고, R3및 R4는 각각 메틸이고, R5는 -CN 또는 -NO2이고, R6는 수소이고, R7은 수소, 메틸, 에틸, 페틸 또는 페닐메틸이고, R8는 수소이고, R9는 수소이고, R10은 수소이고, n은 1이다.
  4. 제1항에 있어서, 화합물이 (트란스)-N″-시아노-N-(6-시아노-3,4-디히드로-3-히드록시-2,2-디메틸-2H-1-벤조피란-4-일)-N'-(1,1-디메틸프로필)구아니딘인 화합물.
  5. 제1항에 있어서, 화합물이 (트란스)-N″-시아노-N-(6-시아노-3,4-디히드로-3-히드록시-2,2-디메틸-2H-1-벤조피란-4-일)-N'-에틸구아니딘인 화합물.
  6. 제1항에 있어서, 화합물이 (트란스)-N″-시아노-N-(6-시아노-3,4-디히드로-3-히드록시-2,2-디메틸-2H-1-벤조피란-4-일)-N'-페닐구아니딘인 화합물.
  7. 제1항에 있어서, 화합물이 (트란스)-N″-시아노-N-(6-시아노-3,4-디히드로-3-히드록시-2,2-디메틸-2H-1-벤조피란-4-일)-N'-에틸구아니딘인 화합물.
  8. 제1항에 있어서, 화합물이 (트란스)-3,4-디히드로-3-히드록시-2,2-디메틸-4-[2-(시아노이미노-1-피롤리디닐]-2H-1-벤조피란-6-카르보니트릴인 화합물.
  9. 제1항에 있어서, 화합물이 (트란스)-N″-시아노-N-(3,4-디히드로-3-히드록시-2,2-디메틸-2H-피라노[3,2-c]피리딘-4-일)-페닐구아니딘인 화합물.
  10. 제1항에 있어서, 화합물이 (트란스)-N″-시아노-N-(6-시아노-3,4-디히드로-3-히드로시-2,2-디메틸-2H-1-벤조피란-4-일)-1-피롤리딘-카르복스이미다미드인 화합물.
  11. 제1항에 있어서, 화합물이 (트란스)-N″-시아노-N-(6-시아노-3,4-디히드로-3-히드로시-2,2-디메틸-2H-1-벤조피란-4-일)-N'-에틸-N-메틸구아니딘인 화합물.
  12. 제1항에 있어서, 화합물이 (트란스)-N″-시아노-N-(6-시아노-3,4-디히드로-3-히드록시-2,2-디메틸-2H-1-벤조피란-4-일)-N'-[2(디메틸아미노)에틸]구아니딘인 화합물.
  13. 제1항에 있어서, 화합물이 (트란스)-4[[(시아노이미노)(1-피롤리디닐)-메틸]아미노]-3,4-디히드록시-2,2-디메틸-2H-1-벤조피란-6-카르보니트릴인 화합물.
  14. 제1항에 있어서, 화합물이 (트란스)-N″-시아노-N-(6-시아노-3,4-디히드로-3-히드록시-2,2-디메틸-2H-1-벤조피란-4-일)-N'-메틸구아니딘인 화합물.
  15. 제1항에 있어서, 화합물이 (트란스)-4[(시아노이미노)[[4-(페닐메틸)-1-피페라지닐]메틸]아미노-3,4-디히드로-3-히드록시-2,2-디메틸-2H-1-벤조피란-6-카르보니트릴인 화합물.
  16. 제1항에 있어서, 화합물이 (트란스)-N″-시아노-N-(6-시아노-3,4-디히드로-3-히드록시-2,2-디메틸-2H-1-벤조피란-4-일)구아니딘인 화합물.
  17. 제1항에 있어서, 화합물이 (트란스)-N″-시아노-N-(6-시아노-3,4-디히드로-3-히드록시-2,2-디메틸-2H-1-벤조피란-4-일)-N'-(메틸에틸)구아니딘인 화합물.
  18. 제1항에 있어서, 화합물이 (트란스)-N″-시아노-N-(6-시아노-3,4-디히드로-3-히드록시-2,2-디메틸-2H-1-벤조피란-4-일)-N'-디메틸구아니딘인 화합물.
  19. 제1항에 있어서, 화합물이 (트란스)-N″-시아노-N-(6-시아노-3,4-디히드로-3-히드록시-2,2-디메틸-2H-1-벤조피란-4-일)-N'-페닐메틸구아니딘인 화합물.
  20. 제1항에 있어서, 화합물이 (트란스)-N″-시아노-N-(6-시아노-3,4-디히드로-3-히드록시-2,2-디메틸-2H-1-벤조피란-4-일)-N'-[2-[(페틸메틸)메틸아미노]에틸]구아니딘인 화합물.
  21. 제1항에 있어서, 화합물이 (트란스)-N″-시아노-N-(6-시아노-3,4-디히드로-3-히드록시-2,2-디메틸-2H-1-벤조피란-4-일)-N'-(2-메록시에틸)구아니딘인 화합물.
  22. 제1항에있어서, 화합물이 (3S-트란스)-N″-시아노-N-(6-시아노-3,4-디히드로-3-히드록시-2,2-디메틸-2H-1-벤조피란-4-일)-N'-페닐구아니딘인 화합물.
  23. 제1항에있어서, 화합물이 (3S-트란스)-N″-시아노-N-(6-시아노-3,4-디히드로-3-히드록시-2,2-디메틸-2H-1-벤조피란-4-일)-N'-페닐구아니딘인 화합물.
  24. 제1항에 있어서, 화합물이 (트란스)-4-[2-(시아노이미노)테트라히드로-1-(2H)-피리미디닐]-3,4-디히드로-3-히드록시-2,2-디메틸-2H-1-벤조피란-6-카르보니트릴인 화합물.
  25. 제1항에 있어서, 하기 구조식을 갖는 화합물.
  26. 제1항에 정의한 바와 같은 화합물의 치료학적으로 유효한 양을 치료를 요하는 포유류 동물종에 투여함을 특징으로 하는 심근성 허혈증의 치료 방법.
  27. 제26항에 있어서, 상기 호합물에 있어서, R7이 아릴 및 아릴아킬중에서 선택되고, R8및 R9이 각각 수소인 방법.
  28. 제26항에 있어서, 상기 화합물이 하기 구조식을 갖는 방법.
  29. 제1항의 화합물의 치료학적으로 유효한 양을 치료를 요하는 포유류 동물종에 투여함을 특징으로 하는 고혈압 치료의 방법.
  30. 제29항에 있어서, 상기 화합물에서 R7이 수소 및 1 내지 3개의 탄소 원자를 갖는 알킬기 중에서 선택되거나, 또는 R7및 R8이 함께 피롤리딘 또는 피페리딘을 형성하고, R9및 R10이 각각 수소이고, n이 1 또는 2인 방법.
  31. 제1항에 있어서, 화합물이 (트란스)-N″-시아노-N-(6-시아노-3,4-디히드로-3-히드록시-2,2-디메틸-2H-1-벤조피란-4-일)-N'-(2-메톡시에틸)구아니딘인 화합물.
  32. 제1항에 있어서, 화합물이 (트란스)-N″-시아노-N-(6-시아노-3,4-디히드로-3-히드록시-2,2-디메틸-2H-1-벤조피란-4-일)-N'-(4-피리디메틸)구아니딘인 화합물.
  33. 제1항에 있어서, 화합물이 (트란스)-N″-시아노-N-(6-시아노-3,4-디히드로-3-히드록시-2,2-디메틸-2H-1-벤조피란-4-일)-N'-(3-피리디닐메틸)구아니딘인 화합물.
  34. 제1항에 있어서, 화합물이 (트란스)-N″-시아노-N-(6-에티닐-3,4-디히드로-3-히드록시-2,2-디메틸-2H-1-벤조피란-4-일)-N'-페닐구아니딘인 화합물.
  35. 제1항에 있어서, 화합물이 (트란스)-N″-시아노-N-(3,4-디히드로-6-(페닐에티닐)-2H-1-벤조피란-4-일)-N'-페닐구아니딘인 화합물.
  36. 하기 일반식을 갖는 피라닐 시아노구아니딘 유도체 화합물.
    식 중, a, b 및 c는 모두 탄소 원자이거나, 또는 a, b 및 c중 하나는 질소 원자 또는 -NO- 이고, 나머지는 탄소 원자들이고,
    R2는 수소, 히드록시,이고, R3및 R4는 각각 독립적으로 수소, 알킬 또는 아릴알킬이거나, 또는 R3및 R4는 이들에 결합된 탄소 원자와 함께 5 내지 7원 카르보시클릭 고리를 형성하고, R5는 H, 알킬, 할로알킬, 알케닐, 알키닐, 시클로알킬, 아릴알킬, 시클로알킬알킬, -CN, -NO2, -COOR, -CONHR, -CONR2, -CF3, S-알킬, -SO알킬, -SO2알킬, 할로겐, 아미노, 치환된 아미노 O-알킬, OCF3, OCH2CF3, OCO알킬, -OCONR 알킬, -NRCO알킬 및 NRCOO알킬, NRCONR2(여기서, 상기 기들 중에서, R은 수소, 알킬, 아릴, 아릴알킬, 시클로알킬, 또는 시클로알킬알킬기일 수 있음)중에서 선택되고, R6는 H, 알킬, OH, O-알킬, 아미노, 치환 아미노, CN, 및 NO2중에서 선택되고, R7과 R8은 각각 독립적으로 수소, 알킬, 알케닐, 아릴, 아릴알킬, 헤테로시클로, 시클로알킬 및 시클로알킬알킬중에서 선택되거나, 또는 R7및 R8은 이들에 결합된 질소원자와 함게 1-피롤리디닐, 1-피페리디닐, 1-아제피닐, 4-모르폴리닐, 4-티아모르필리닐, 1-피페라지닐, 4-알킬-1-피페라지닐 또는 4-아릴알킬-1-페페라지닐기를 형성할 수 있고, 여기서, 이와 같이 형성된 기들은 각각 알킬, 알콕시, 알킬티오, 할로겐 또는 트리플루오로메틸기로 치환될 수 있으며, R9와 R10은 수소, 알킬,알케닐, 아릴, 알릴알킬, 시클로알킬 또는 시클로알킬알킬기 중에서 선택되고; n은 1,2 또는 3이다.
    ※ 참고사항 : 최초출원내용에 의하여 공개하는 것임.
KR1019900007840A 1989-05-31 1990-05-30 피라닐 시아노구아니딘 유도체 KR950006155B1 (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US35923689A 1989-05-31 1989-05-31
US359,236 1989-05-31
US359236 1989-05-31
US49306090A 1990-03-13 1990-03-13
US493,060 1990-03-13
US493060 1990-03-13

Publications (2)

Publication Number Publication Date
KR900018064A true KR900018064A (ko) 1990-12-20
KR950006155B1 KR950006155B1 (ko) 1995-06-09

Family

ID=27000402

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900007840A KR950006155B1 (ko) 1989-05-31 1990-05-30 피라닐 시아노구아니딘 유도체

Country Status (22)

Country Link
EP (1) EP0401010B1 (ko)
JP (2) JPH0327375A (ko)
KR (1) KR950006155B1 (ko)
CN (1) CN1047672A (ko)
AT (1) ATE141598T1 (ko)
AU (1) AU633082B2 (ko)
CA (1) CA2015296C (ko)
DE (1) DE69028143T2 (ko)
DK (1) DK0401010T3 (ko)
EG (1) EG19389A (ko)
ES (1) ES2090099T3 (ko)
FI (1) FI109120B (ko)
GR (1) GR3021702T3 (ko)
HK (1) HK16997A (ko)
HU (1) HU207857B (ko)
IE (1) IE901793A1 (ko)
IL (1) IL94326A (ko)
NO (1) NO174807B (ko)
NZ (1) NZ233845A (ko)
PL (4) PL166192B1 (ko)
PT (1) PT94210B (ko)
RU (1) RU2057129C1 (ko)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ231969A (en) * 1988-12-23 1992-09-25 Beecham Group Plc Benzopyran derivatives, analogues, precursors, and medicaments
US5104890A (en) * 1989-03-28 1992-04-14 Fujisawa Pharmaceutical Company, Ltd. Benzopyran derivatives and processes for preparation thereof
US5140031A (en) * 1989-05-31 1992-08-18 E. R. Squibb & Sons, Inc. Pyranyl cyanoguanidine derivatives
CA2015296C (en) * 1989-05-31 2001-08-07 Karnail Atwal Pyranyl cyanoguanidine derivatives
FR2657872B2 (fr) * 1989-11-06 1992-06-12 Sanofi Sa Derive d'amidino-4 chromanne, procede d'obtention et compositions pharmaceutiques le contenant.
RU2102547C1 (ru) * 1990-05-17 1998-01-20 Юнион Кемп Корпорейшн Способ получения отбеленной целлюлозной массы и способ делигнификации и отбелки лигноцеллюлозного материала (варианты)
AU651105B2 (en) * 1990-06-18 1994-07-14 E.R. Squibb & Sons, Inc. Benzopyran derivatives and heterocyclic analogs thereof as antiischemic agents
US5643921A (en) * 1990-09-26 1997-07-01 E.R. Squibb & Sons, Inc. Cardiopulmonary bypass and organ transplant using a potassium channel activator
CA2055376A1 (en) * 1990-12-05 1992-06-06 Gary J. Grover Method of treating shock using a potassium channel activator
DE4120322A1 (de) * 1991-06-20 1992-12-24 Bayer Ag Aminomethyl-substituierte 2,3-dihydropyrano(2,3-b)pyridine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
US5374643A (en) * 1992-09-11 1994-12-20 E. R. Squibb & Sons, Inc. Aryl urea (thiourea) and cyanoguanidine derivatives
IL109229A0 (en) * 1993-05-11 1994-07-31 Bristol Myers Squibb Co Heterocyclic compounds and processes for the preparation of pyranyl cyanoguanidine derivatives using the same
US5478734A (en) * 1993-06-18 1995-12-26 Bristol-Myers Squibb Company Method of chiral epoxidation of benzopyran or pyranopyridine derivatives using microorganisms
US5869478A (en) * 1995-06-07 1999-02-09 Bristol-Myers Squibb Company Sulfonamido substituted benzopyran derivatives
US5612323A (en) * 1995-06-07 1997-03-18 Bristol-Myers Squibb Company Phosphinic ester substituted benzopyran derivatives
US5612370A (en) * 1995-06-07 1997-03-18 Bristol-Myers Squibb Company Phenylglycine and phenylalaninen amido benzopyran derivatives
US5629429A (en) * 1995-06-07 1997-05-13 Bristol-Myers Squibb Company Process for preparing 4-arylamino-benzopyran and related compounds
KR100429609B1 (ko) * 1999-10-21 2004-05-03 동부한농화학 주식회사 벤조피라닐 구아니딘 유도체, 그의 제조방법 및 그를포함하는 약학적 조성물
CN1229371C (zh) * 1999-10-21 2005-11-30 东部韩农化学株式会社 苯并吡喃胍衍生物,其制备方法,及其药物组合物
CN1854135B (zh) * 2005-04-18 2013-06-12 李伟章 由氰基胍连接组成的杂环化合物及其医药应用
WO2007022964A2 (de) 2005-08-24 2007-03-01 Abbott Gmbh & Co. Kg Hetaryl substituierte guanidinverbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
JP5647227B2 (ja) * 2009-04-23 2014-12-24 ピラマル イメージング ソシエテ アノニム Ｆ−１８ラベルされたｐｅｔトレーサーのための新規前駆体分子

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3682331D1 (de) * 1985-06-08 1991-12-12 Beecham Group Plc Pyrano(3,2-c)pyridinderivate, verfahren und zwischenprodukte zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen.
GB8521857D0 (en) * 1985-09-03 1985-10-09 Beecham Group Plc Active compounds
JPH027217A (ja) * 1988-04-30 1990-01-11 Mitsubishi Electric Corp 磁気記録再生装置
US4988723A (en) * 1988-06-02 1991-01-29 Fujisawa Pharmaceutical Co., Ltd. Benzopyran derivatives and their use as anti-hypertensives
DE3823533A1 (de) * 1988-07-12 1990-02-08 Beiersdorf Ag Substituierte 4-heterocyclyl-2h-benzo(b)pyrane, verfahren und 4-hydroxy-3-brom-, 3,4-oxiranyl-3,4-dehydro-2h-benzo(b)pyrane als zwischenprodukte zu ihrer herstellung, sowie sie enthaltende pharmazeutsche praeparate
EP0359537B1 (en) * 1988-09-16 1996-06-26 Beecham Group Plc Benzopyran derivatives with antihypertensive activity
JPH02172984A (ja) * 1988-12-23 1990-07-04 Yamanouchi Pharmaceut Co Ltd クロマン誘導体
US5104890A (en) * 1989-03-28 1992-04-14 Fujisawa Pharmaceutical Company, Ltd. Benzopyran derivatives and processes for preparation thereof
CA2015296C (en) * 1989-05-31 2001-08-07 Karnail Atwal Pyranyl cyanoguanidine derivatives

Also Published As

Publication number Publication date
IL94326A0 (en) 1991-03-10
PL166230B1 (pl) 1995-04-28
NO902394L (no) 1990-12-03
DE69028143T2 (de) 1997-01-23
HUT55055A (en) 1991-04-29
PL166192B1 (pl) 1995-04-28
HU9003271D0 (en) 1990-10-28
RU2057129C1 (ru) 1996-03-27
NO174807C (ko) 1994-07-13
EP0401010A2 (en) 1990-12-05
HU207857B (en) 1993-06-28
EP0401010A3 (en) 1991-05-02
IE901793A1 (en) 1991-09-25
DE69028143D1 (de) 1996-09-26
AU633082B2 (en) 1993-01-21
CA2015296C (en) 2001-08-07
JPH0327375A (ja) 1991-02-05
PT94210A (pt) 1991-02-08
PL166007B1 (pl) 1995-03-31
FI902710A0 (fi) 1990-05-31
PT94210B (pt) 1997-07-31
CA2015296A1 (en) 1990-11-30
ATE141598T1 (de) 1996-09-15
EP0401010B1 (en) 1996-08-21
NO174807B (no) 1994-04-05
GR3021702T3 (en) 1997-02-28
PL285415A1 (en) 1991-09-09
FI109120B (fi) 2002-05-31
IE901793L (en) 1990-11-30
PL166174B1 (pl) 1995-04-28
NZ233845A (en) 1994-09-27
ES2090099T3 (es) 1996-10-16
DK0401010T3 (da) 1996-09-16
CN1047672A (zh) 1990-12-12
JPH05239049A (ja) 1993-09-17
KR950006155B1 (ko) 1995-06-09
AU5455290A (en) 1990-12-06
IL94326A (en) 1995-12-08
NO902394D0 (no) 1990-05-30
EG19389A (en) 1995-02-28
HK16997A (en) 1997-02-13

Similar Documents

Publication Publication Date Title
KR900018064A (ko) 피라닐 시아노구아니딘 유도체
KR920009783A (ko) 인단 및 퀴놀린 유도체
RU99108663A (ru) Производные хиназолина и содержащие их фармацевтические композиции
KR920016437A (ko) 피라닐 시아노구아니딘 유도체
KR880008986A (ko) D 계열 프로스타글란딘, 및 그를 함유하는 정신안정제와 최면제
ES2059391T3 (es) Derivados de dihidropiridina, su preparacion y su uso.
KR920000742A (ko) 항허혈제로서 유용한 벤조피란 유도체 및 그의 헤테로시클릭 유사체
KR930700490A (ko) 탄산탈수효소 억제제로서 유용한 티오펜 설폰아미드
KR910007908A (ko) 신규 화합물들
RU2001101466A (ru) Новые производные бензопирана или тиобензопирана
KR900003127A (ko) 강심제
EA199800278A1 (ru) Пентациклические соединения, промежуточные соединения, способы, композиции и методы
RU2004133670A (ru) Способ лечения диабета
DE3575132D1 (de) 2-phenylalkyl-3-aminoalkyl-4(3h)-chinazolinonen, verfahren zu deren herstellung, pharmazeutische zusammenstellungen und verwendung.
KR910016660A (ko) 스쿠알렌 에폭시다제 억제제로서의 스쿠알렌의 디-및 테트라-플루오르 유사체
KR940003953A (ko) 1. 4-벤조디옥산 유도체
DE3881817D1 (de) 3,5-dihydroxy-6,8-nonadiensaeuren und -derivate als hypocholesterolemische mittel.
KR910006309A (ko) 인지질 및 인지질 유도체를 유효 성분으로 하는 항비루스성 약제
EA200100059A3 (ru) Новые бензолсульфонамидные производные, способ их получения и содержащие их фармацевтические композиции
HU911992D0 (en) 2-(amino-alkyl)-5-(aryl-alkyl)-1,3-dioxanes, and process for the production of the medical preparations containing them
ATE115124T1 (de) Thionaphthalen-derivate, verfahren zur herstellung und antiallergisches mittel daraus.
KR910002834A (ko) 신규 화합물
CA2014521A1 (en) 2-Substituted N,N'-Ditrimethoxybenzoyl Piperazines, a Preparation Process of the Same and Therapeutic Compositions Containing Them
ATE41659T1 (de) Benzothiazepinderivate, verfahren zur herstellung und pharmazeutische zusammensetzungen.
EA200501136A1 (ru) Триазольные соединения, полезные в терапии

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20080522

Year of fee payment: 14

LAPS Lapse due to unpaid annual fee